Gilead Sciences, Inc. (NASDAQ:GILD) Chief Medical Officer Merdad Parsey has recently engaged in significant trading activity, according to the latest filings with the Securities and Exchange ...

Gilead Sciences, Inc. (NASDAQ:GILD) Chief Medical Officer Merdad Parsey has recently engaged in significant trading activity, according to the latest filings with the Securities and Exchange ...

Gilead Sciences' chief medical officer, Merdad Parsey, will leave the company in early 2025, becoming the latest in a series of high-profile departures involving senior R&D figures at top drugmakers.

Gilead Sciences, Inc. (Nasdaq: GILD) will present new data from the company’s broad lung cancer clinical development program ...

“Our data at WCLC will add to the expanding evidence for the potential of Trodelvy in lung cancer and reinforce our confidence in our broader lung cancer strategy,” said Merdad ...

FOSTER CITY, Calif., September 05, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) will present new data from the company’s broad lung cancer clinical development program during the IASLC 2024 World ...

Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $81.44 which represents a slight increase of $2.27 or 2.87% from the prior close of $79.17. The stock opened at $79.17 and ...

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $78.77 which represents a decrease of $-0.36 or -0.45% from the prior close of $79.13. The stock opened at $78.95 and touched a low ...

"This is a significant milestone for Gilead and, more importantly, for patients diagnosed with these cancers," said the company's chief medical officer Merdad Parsey. "We look forward to ...